Dave Fellows, Beacon Therapeutics CEO
June 11, 2023 07:01 PM EDTUpdated June 12, 04:55 AM
Financing
Startups
Cell/Gene Tx

Ex-Night­star, Gy­ro­scope and AGTC teams try again for next reti­nal gene ther­a­py with $120M for Bea­con Ther­a­peu­tics

Kyle LaHucik

Senior Reporter

Life sci­ences in­vestor Syn­cona is tak­ing a sec­ond shot at X-linked re­tini­tis pig­men­tosa, this time with Bea­con Ther­a­peu­tics, a reti­nal gene ther­a­py start­up led by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times